Friday, July 10, 2026

pharma · Glaucoma · Macular Edema

Allergan Pharmaceuticals International

Allergan Pharmaceuticals International is a pharma organization headquartered in Dublin, IE. Primary therapeutic focus areas include Glaucoma, Macular Edema, Macular Degeneration, Dry Eye Syndromes, Choroid Neovasculariz

Dublin, IE HQ
EMA registrant Type
Company details
Clinical program

Brimo PS DDS®

Phase 2 · small molecule · Patients Who Participated in an Intravitreal Brimo PS DDS® Study

Brimo PS DDS® for Patients Who Participated in an Intravitreal Brimo PS DDS® Study is a Phase 2 program (small_molecule) at Allergan Pharmaceuticals International Limited with 1 ClinicalTrials.gov record(s).

Internal code 190342-033D

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Allergan Pharmaceuticals International Limited
Phase
Phase 2
Modality
small_molecule
Indication
Patients Who Participated in an Intravitreal Brimo PS DDS® Study
Status
completed
Trials
1